March 21, 2022
Bluetail Medical Group Receives FDA IDE Approval for Pivotal Study of the Use of Cellular Therapy
BMG is pleased to announce that the FDA has approved the company's Investigational Device Exemption application, permitting BMG to begin a feasibility study of cellular therapy in the treatment of knee osteoarthritis.










